EuroAPI overhaul comes into focus with plans to cut 550 staffers and divest two facilities

Anna Brown

News Reporter

Sanofi spin-off EuroAPI provided further details on its restructuring plan, with the company cutting 550 staffers and divesting two facilities — one in Brindisi, Italy, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EuroAPI overhaul comes into focus with plans to cut 550 staffers and divest two facilities

Anna Brown

News Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Immunology biotech Alumis secures $250M in shrunken IPO

Eu­roAPI over­haul comes in­to fo­cus with plans to cut 550 staffers and di­vest two fa­cil­i­ties

Anna Brown

News Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

EuroAPI overhaul comes into focus with plans to cut 550 staffers and divest two facilities

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Immunology biotech Alumis secures $250M in shrunken IPO